Compositions for preventing and treating digestive organs diseases

Abstract

The present invention provides a composition for safely and effectively preventing and treating digestive organs diseases, particularly, gastric ulcer, duodenal ulcer, gastritis, diarrhea, enteritis and the like. There is also provided a composition having a novel mechanism of action in order to solve the problems which was difficult to be solved by the side effect previously known mechanisms of action. More particularly, there is provided a pharmaceutical composition containing an ingredient which activates PAR-2 as an essential ingredient, which is useful for inhibiting gastric acid secretion, promoting digestive tract mucus secretion, protecting digestive tract mucosa, repairing tissue of digestive organs, and preventing and treating digestive organs diseases.

What is claimed is:  
     
         1 . A composition for inhibiting gastric acid secretion, comprising an ingredient which activates PAR-2.  
     
     
         2 . A composition for promoting gastrointestinal mucus secretion, comprising an ingredient which activates PAR-2.  
     
     
         3 . A composition for protecting gastrointestinal mucosa, comprising an ingredient which activates PAR-2.  
     
     
         4 . A composition for preventing or treating digestive organs diseases, comprising an ingredient which activates PAR-2.  
     
     
         5 . The composition according to  claim 4 , wherein the digestive organs disease is the disease selected from gastric ulcer, duodenal ulcer, gastritis, diarrhea, and enteritis.  
     
     
         6 . The composition according to any one of claims  1 - 5 , wherein the ingredient is a peptide.  
     
     
         7 . The composition according to  claim 6 , wherein the peptide comprises at least one sequence selected from the group consisting of Ser-Leu-Ile-Gly-Arg-Leu-NH 2  (SEQ ID NO: 1) and trans-cinnamoyl-Leu-Ile-Gly-Arg-Leu-ornithine-NH 2  (SEQ ID NO: 2).  
     
     
         8 . The composition according to any one of claims  1 - 5 , wherein the ingredient is a protein.  
     
     
         9 . The composition according to  claim 8 , wherein the protein is at least one selected from trypsin and tryptase.  
     
     
         10 . The composition according to any one of claims  1 - 9 , which is combined with an inhibitory substance which inhibits an activity of substance for inactivating or degrading the ingredient.  
     
     
         11 . The composition according to  claim 10 , which is used together with an inhibitory substance which inhibits an activity of substance for inactivating or degrading the ingredient.  
     
     
         12 . The composition according to  claim 10 , which is incorporated with an inhibitory substance which inhibits an activity of substance for inactivating or degrading the ingredient.  
     
     
         13 . The composition according to any one of claims  10 - 12 , wherein the inhibitory substance is a peptidase inhibitor.  
     
     
         14 . The composition according to  claim 13 , wherein the peptidase inhibitor is amastatin.  
     
     
         15 . The composition according to any one of claims  1 - 14 , which is formulated into a DDS preparation.